MT-501

DRUG3 trials

Sponsors

Mirador Therapeutics Inc., Mirador Therapeutics, Inc.

Conditions

Crohn's DiseaseCrohn’s DiseaseHealthy VolunteersInflammatory Bowel Disease (IBD)Ulcerative ColitisUlcerative Colitis (UC)

Phase 1

A First-in-Human Single and Multiple Ascending Dose Study of MT-501

CompletedNCT06762457

Mirador Therapeutics, Inc.Healthy Volunteers

Start: 2024-12-11End: 2025-05-22Updated: 2025-11-28

Phase 2

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

RecruitingNCT07113522

Mirador Therapeutics, Inc.Crohn's Disease, Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC)

Start: 2025-06-26End: 2028-02-04Target: 140Updated: 2026-03-12

A Phase 2, Multi-Center, Platform Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics with Multiple Therapies in Participants with Active Crohn’s Disease or Active Ulcerative Colitis (ASCEND-IBD)

Not yet recruitingCTIS2025-522001-38-00

Mirador Therapeutics Inc.Crohn’s Disease, Ulcerative Colitis

Target: 54Updated: 2025-10-26